Associated tags: Patient, Brain, Stroke, Concussion, Traumatic brain injury, Drug discovery, Biotechnology, Science, Pharmaceutical industry, Therapy, Clinical Trials, Research, Neurology, Pharmaceutical, Health, Astrocyte, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co.
Locations: GROTON, CONNECTICUT, US, EUROPE
Diagnosis,
Stroke,
Brain,
Patient,
Concussion,
TBI,
Death,
IND,
Traumatic brain injury,
Investigational New Drug,
Yale school,
FDA,
Health,
Food,
Pharmaceutical industry The IND application clearance also paves the way for additional studies further exploring AST-004 in stroke, as well as TBI, and concussion.
Key Points:
- The IND application clearance also paves the way for additional studies further exploring AST-004 in stroke, as well as TBI, and concussion.
- And it has the potential to treat stroke occurring in any sized blood vessel in the brain.
- Astrocyte previously completed two Phase 1 safety trials in Europe, involving 80 participants in total, and saw no significant adverse effects or safety concerns.
- Dr. William Korinek, CEO of Astrocyte Pharmaceuticals, commented, “Since our founding in 2014, we have been focused on demonstrating the potential of cerebroprotective benefits of AST-004.
Biotechnology,
Professional Services,
Health,
General Health,
Pharmaceutical,
Neurology,
Mental Health,
Research,
Science,
Clinical Trials,
Finance,
Fillit,
Therapy,
Face,
Drug discovery,
Astrocyte,
Stroke,
Brain,
TBI,
Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co.,
Inflammation,
Patient,
Alzheimer's Drug Discovery Foundation,
Traumatic brain injury,
Medicine,
Entrepreneurship,
Pharmaceutical industry,
Alzheimer's disease Astrocyte Pharmaceuticals Inc. , a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors.
Key Points:
- Astrocyte Pharmaceuticals Inc. , a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors.
- “There are millions of patients living with brain injuries worldwide who face limited treatment options for these devastating conditions,” said William Korinek, Ph.D, CEO, Astrocyte Pharmaceuticals.
- “Astrocyte has assembled an exceptional team of experts that are conducting research of the highest quality at every step,” commented Gorka Fius, CEO at Dreavent Capital who led the investment round.
- “Finding innovative ways to target inflammation in the brain will play an important role in the future of combination therapy and precision medicine for Alzheimer's disease,” said Howard Fillit, M.D., Co-Founder and Chief Science Officer, Alzheimer's Drug Discovery Foundation.
Science,
Neurology,
Cardiology,
Biotechnology,
Research,
Pharmaceutical,
Health,
Clinical Trials,
Adenosine A1 receptor,
University,
Chicago Innovation Awards,
Therapy,
Interview,
American Heart Association,
COVID-19,
Yale Center for Environmental Law & Policy,
University of Warwick,
Innovation,
Multimedia,
Daubert v. Merrell Dow Pharmaceuticals, Inc.,
Progress,
Associate,
Splenic infarction,
Data analysis,
Publication,
Patient,
Brain,
Risk,
Primate,
Russell,
Cerebrovascular disease,
University of Texas Health Science Center at San Antonio,
J. Anthony Lukas Work-in-Progress Award,
Nursing care plan,
Rush University Medical Center,
Adenosine,
Pharmaceutical industry,
Astrocyte,
Stroke The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.”
Key Points:
- The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.”
This press release features multimedia.
- The study showed compelling benefits for AST-004 treatment slowing stroke lesion growth, preserving at risk penumbra tissue, and substantially reducing the amount of brain tissue lost to the stroke.
- The Progress and Innovation Award is given to the publication’s first author and is comprised of a cash prize and a trophy.
- “The ongoing excitement of endovascular reperfusion has heralded a resurgence of scientific development aimed at improving acute stroke outcomes.
Health,
Neurology,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Manna,
Therapy,
Pharmacokinetics,
Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co.,
Patient,
Brain,
United States Army Medical Research and Development Command,
Drug discovery,
QPS,
MTEC,
Safety,
Pharmaceutical industry Astrocyte Pharmaceuticals Inc. , a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers.
Key Points:
- Astrocyte Pharmaceuticals Inc. , a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers.
- This adaptive-design clinical study will be conducted over the next four to six months at the QPS clinical research site in Groningen, Netherlands.
- A Phase 1A study completed in 2022 with single ascending 10-minute bolus doses of AST-004 showed no significant adverse effects or safety signals.
- “Astrocyte is committed to developing innovative therapies that treat brain injuries and improve the lives of patients,” said Lisa Manna, Astrocyte’s Vice President of Clinical Development Operations.
